Email updates

Keep up to date with the latest news and content from BMC Pulmonary Medicine and BioMed Central.

Open Access Highly Accessed Research article

Efficacy and safety of inhaled formoterol 4.5 and 9 μg twice daily in Japanese and European COPD patients: Phase III study results

Miron A Bogdan1*, Hisamichi Aizawa2, Yoshinosuke Fukuchi3, Michiaki Mishima4, Masaharu Nishimura5 and Masakazu Ichinose6

Author Affiliations

1 Clinica Medic Or, Calea Vitan no 106, Postcode 031298, Bucharest, Romania

2 Kurume University, 67 Asahi-cho, Kurume-shi, Fukuoka 830-0011, Japan

3 Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Tokyo, Japan

4 Kyoto University, Yoshidakonoe-cho, Sakyo-ku, Kyoto-shi, Kyoto 606-8501, Japan

5 Hokkaido University, Nishi 7-chome, Kita 15-jo, Kita-ku, Sapporo-shi, Hokkaido 060-8638, Japan

6 Wakayama Medical University, 811-1 Kimiidera, Wakayama-shi, Wakayama 641-8509, Japan

For all author emails, please log on.

BMC Pulmonary Medicine 2011, 11:51  doi:10.1186/1471-2466-11-51

Published: 15 November 2011

Abstract

Background

This study evaluated the efficacy and safety of the long-acting β2-agonist formoterol in patients with moderate-to-severe COPD.

Methods

This double-blind, placebo-controlled, parallel-group, multinational phase III study randomized patients ≥ 40 years of age with moderate-to-severe COPD to inhaled formoterol 4.5 or 9 μg twice daily (bid) via Turbuhaler® or placebo for 12 weeks. Salbutamol 100 μg/actuation via pMDI was permitted as reliever medication. The primary outcome variable was change (ratio) from baseline to treatment period in FEV1 60-min post-dose.

Results

613 patients received treatment (formoterol 4.5 μg n = 206; 9 μg n = 199; placebo n = 208); 539 (87.9%) male; 324 (52.9%) Japanese and 289 (47.1%) European. End of study increases in FEV1 60-min post-dose were significantly greater (p < 0.001 for both) with formoterol 4.5 and 9 μg bid (113% of baseline for both) than with placebo, as were all secondary outcome measures. The proportion of patients with an improvement in St George's Respiratory Questionnaire score of ≥ 4 was 50.2% for formoterol 4.5 μg (p = 0.0682 vs. placebo), 59.2% (p = 0.0004) for 9 μg, and 41.3% for placebo. Reduction in reliever medication use was significantly greater with formoterol vs. placebo (9 μg: -0.548, p < 0.001; 4.5 μg: -0.274, p = 0.027), with 9 μg being significantly superior to 4.5 μg (-0.274, p = 0.029). Formoterol was well tolerated with the incidence and type of adverse events not being different for the three groups.

Conclusions

Formoterol 4.5 μg and 9 μg bid was effective and well tolerated in patients with COPD; there was no difference between formoterol doses for the primary endpoint; however, an added value of formoterol 9 μg over 4.5 μg bid was observed for some secondary endpoints.

Trial registration

NCT00628862 (ClinicalTrials.gov); D5122C00001 (AstraZeneca Study code).